Tagged with “Fusilev”

Colorectal Cancer News in Brief: October 9

Briefly: In research this week, human embryonic stem cells produced an immune response in mice with colon cancer, and discussing strong pain medicines with cancer patients reduces their pain by about 20 percent.

The Food and Drug Administration has found many dietary supplements contaminated with prescription drugs not listed on the label, some at several times higher than the recommended dose. In other FDA news, Spectrum Pharmaceuticals was unable to get FDA approval for use of Fusilev® for metastatic colorectal cancer. Continue reading…

Posted by Kate Murphy on October 10th, 2009
Posted in: Research & Treatment News | No Comments »
Tags: dietary supplements, FDA, Fusilev, painkillers, stem cells

Search C3

Free Patient Webinar

Stage II Colon Cancer: Chemo or Not? Find Your Solution
Monday, September 20, 2010
8:00 PM - 9:00 PM EDT

Stage II colon cancer patients face tough decisions about whether the possible benefits of chemotherapy outweigh its risks and challenges. This webinar will explore the answers with you.

Follow C3

Join us on Facebook

Watch us on YouTube

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.